Foghorn Therapeutics Inc.
FHTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $295,998 | $229,398 | $295,485 |
| - Cash | $89,334 | $73,822 | $61,026 | $55,454 |
| + Debt | $15,774 | $23,698 | $34,852 | $37,131 |
| Enterprise Value | – | $245,874 | $203,224 | $277,162 |
| Revenue | $8,153 | $7,557 | $5,952 | $2,856 |
| % Growth | 7.9% | 27% | 108.4% | – |
| Gross Profit | -$11,849 | $6,657 | $5,952 | $2,856 |
| % Margin | -145.3% | 88.1% | 100% | 100% |
| EBITDA | -$14,997 | -$17,036 | -$22,086 | -$23,244 |
| % Margin | -183.9% | -225.4% | -371.1% | -813.9% |
| Net Income | -$15,849 | -$17,936 | -$18,834 | -$19,503 |
| % Margin | -194.4% | -237.3% | -316.4% | -682.9% |
| EPS Diluted | -0.25 | -0.28 | -0.3 | -0.31 |
| % Growth | 10.7% | 6.7% | 3.2% | – |
| Operating Cash Flow | -$18,860 | -$21,000 | -$23,968 | -$24,519 |
| Capital Expenditures | $0 | -$22 | -$28 | -$479 |
| Free Cash Flow | -$18,860 | -$21,022 | -$23,996 | -$24,998 |